ArticleAntimicrobial agents and chemotherapy2013
Target gene sequencing to define the susceptibility of Neisseria meningitidis to ciprofloxacin.
Article in Antimicrobial agents and chemotherapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 41 citations in OpenAlex.
- Investigation of invasiveFrontiers in public health · 2025Article
- CharacterizingIJID regions · 2024Article
- Outbreak of Sexually Transmitted Nongroupable Neisseria meningitidis-Associated Urethritis, Vietnam.Emerging infectious diseases · 2023Article
- Meningococcal Antibiotic Resistance: Molecular Characterization of Isolates from Patients with Invasive Meningococcal Disease (IMD) in Greece.Antibiotics (Basel, Switzerland) · 2023Article
- Antimicrobial susceptibility profiles and genotyping ofFrontiers in microbiology · 2023Article
- Enhancing Meningococcal Genomic Surveillance in the Meningitis Belt Using High-Resolution Culture-Free Whole-Genome Sequencing.The Journal of infectious diseases · 2022Article
- Demographic Features of Invasive Meningococcal Disease in Taiwan, 1993 to 2020, and Genetic Characteristics of Neisseria meningitidis Isolates, 2003 to 2020.Microbiology spectrum · 2022Article
- Antimicrobial Susceptibility Survey of Invasive Neisseria meningitidis, United States 2012-2016.The Journal of infectious diseases · 2022Article
- Surveillance and control of meningococcal disease in the COVID-19 era: A Global Meningococcal Initiative review.The Journal of infection · 2022Review
- Molecular detection of fluoroquinolone-resistantFrontiers in cellular and infection microbiology · 2022Article
- The resistance mechanisms of bacteria against ciprofloxacin and new approaches for enhancing the efficacy of this antibiotic.Frontiers in public health · 2022Review
- Horizontal Gene Transfer of Fluoroquinolone Resistance-Conferring Genes From CommensalFrontiers in microbiology · 2022Article
- Acquisition of Ciprofloxacin Resistance Among an Expanding Clade of β-Lactamase-Positive, Serogroup Y Neisseria meningitidis in the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Antibiotic susceptibility and molecular analysis of invasive Neisseria meningitidis recovered in the Republic of Ireland, 1996 to 2016.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2021Article
- Antibiotic resistance among invasive Neisseria meningitidis isolates in England, Wales and Northern Ireland (2010/11 to 2018/19).PloS one · 2021Article
- First report of meningococcal ciprofloxacin resistance in Greece due to invasive isolates of the sequence type ST-3129.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020Article
- Meningococcal Quinolone Resistance Originated from Several CommensalAntimicrobial agents and chemotherapy · 2020Article
- Article
- Article
- Establishment of the European meningococcal strain collection genome library (EMSC-GL) for the 2011 to 2012 epidemiological year.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Meningococcal gyrA gene sequence data, MICs, and mouse infection were used to define the ciprofloxacin breakpoint for Neisseria meningitidis. Residue T91 or D95 of GyrA was altered in all meningococcal isolates with MICs of ≥ 0.064 μg/ml but not among isolates with MICs of ≤ 0.032 μg/ml. Experimental infection of ciprofloxacin-treated mice showed slower bacterial clearance when GyrA was altered. These data suggest a MIC of ≥ 0.064 μg/ml as the ciprofloxacin breakpoint for meningococci and argue for the molecular detection of ciprofloxacin resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.